San Francisco, California
London, United Kingdom
BREAST CANCER: DRUGS FUNDING & TRIALS
Achieving world-class patient outcomes 6 CPD points
A Pink Ribbon event Thursday 23 March 2017, 9-5. Faculty of Pharmaceutical Medicine, London EC1V
Theme of the Day:
To identify issues and discuss potential solutions around achieving best care and treatment for all patients with breast cancer (primary and secondary) in UK, including enhancing options for research into curative treatments for secondary breast cancer.
Although within the UK, generally, treatment of Breast Cancer is good, nevertheless the best possible treatment is not available to every patient with breast cancer who would benefit, within an optimal time-frame, for various reasons which will be discussed through the day.
In addition there is the general problem that secondary breast cancer is incurable currently. The purpose of the day is to explore how current initiatives, together with new unexplored initiatives can be implemented to maximise quality of treatment and cure for breast cancer within UK (and beyond, but the purpose of the day is primarily UK).
Top level movers and shakers and opinion formers in healthcare, regulation, industry, politics, academia, media, third sector
Attendees also include doctors, senior nurses, hospital administrators, other pharma personnel, researchers, civil servants, financiers, economists, lawyers, campaigners, media
9 Registration & coffee + exhibition
9.30 Welcome and introduction – Gerard Dugdill, publisher/coordinator Pink Ribbon
Chair: Dr Kathleen Thompson, pharmaceutical physician, breast cancer patient & author, From Both Ends of the Stethoscope
SECTION ONE – THE PROBLEMS
How effective is the current breast cancer drugs regime?
9.40-10.15 Major issues: limits in availability of new effective treatments for metastatic breast cancer, poor access to clinical trials, inadequate use of data to facilitate research into cure, tissue banking.
Introductions (and introduction to white paper). Group discussion: Chair + patient advocates (Jo Taylor, MetupUK; Alison Dagul, breast and ovarian patient; Julia Bradford, Metup)
What are the key challenges in drug approval and funding?
Increasing breast cancer drug costs due to regulation, prevalence, survival rates, long drug approval time. NICE. UK lagging behind other countries. Funding restraints hindering prescription. Cancer Drugs Fund
10.15-10.30 Medical perspective: cancer funding and research needs
Dr Aleksandra Filipovic, research fellow, department of surgery and cancer, Imperial College London
10.30-10.45 Pharma perspective: regulator approval and drug funding
Dr David Montgomery, medical director, Pfizer Oncology UK
10.45-11 Buyer perspective: providing adequate cancer service and drugs
Ms Raj Nijjar, Lead Cancer Pharmacist, Barts Health NHS Trust & Specialised Cancer Commissioning Pharmacist, NHS England - London Region
11-11.15 Life science + patient perspective: accelerated access review opportunities
Dr Stuart Dollow, Head, Global Clinical Development and Medical Affairs at UCB; Founder - Vermilion Life Sciences; also, external champion to the Accelerated Access Review
11.15-11.30 PANEL: are we clear now on the key challenges for the industry? Problems section speakers
11.30-11.45 Refreshments break
SECTION TWO - THE SOLUTIONS
New ways to make and deliver drugs quickly and effectively
11.45-12 Oncologist focus: new drug possibilities, personalized medicine, genomics
Dr Bhawna Sirohi, Consultant Medical Oncologist, Program Training Director - Medical Oncology, Barts Cancer Institute, London
12-12.30 New ways of doing drug development
Speaker one: New ways of funding research. Lesley Turner, patient advocate, Catalyst Initiative
Speaker two: Professor Jackie Hunter, director, Benevolent Artificial Intelligence
12.30-12.45 Cancer patient data: linking the possibilities
Dr Rachael Brock, national head of cancer registration, National Cancer Registration & Analysis Service, Public Health England (PHE)
12.45-1 Clinical trial database creation: getting it perfect
Sarah Kimber, patient information manager, Cancer Research UK
1-1.15 PANEL: what one thing can we do to enhance innovative research?
Drug development section speakers
1.15-2.15 Lunch & exhibition
AFTERNOON SESSIONS …SOLUTIONS CONTINUED
New approaches for approval, cost and reimbursement
2.15-2.35 Regulatory approval of breast cancer drugs
Dr Cecilia Chisholm, medical assessor in licensing divison, medicines and healthcare products regulatory agency (MHRA)
2.35-2.50 Regulation from an EU perspective
Dr Francesco Pignatti, head of oncology, haematology and diagnostics, European Medicines Agency (EMA)
2.50-3.05 PANEL: how can we get the best possible regulation?
Panel: regulation section speakers+ extra, NHS England, NHS
3.05-3.20 Tea break
Collaboration: getting new drugs to patients
3.20-3.50TOWARDS PARTNERSHIP APPROACHES IN FUNDING
Possible discussion and/or speaker
3.50-4.05 The new Cancer Drugs Fund
Linda Landells, associate director – Technology Appraisals (Cancer Drugs Fund), national institute for clinical excellence (NICE)
4.05-4.25 Making drugs available earlier: how can we achieve?
Professor Peter Clark, clinical lead, CDF, NHS England
4-25-4.45 PANEL: what must we do to fund all patient needs?
Panel: funding section speakers
4.45-5 Chair’s closing remarks + call to action via white paper
A Pink Ribbon event, in aid of the national hereditary breast cancer helpline
Supported by Pfizer Limited
Save This Event
When & Where
Network of professionals and public seeking to eliminate breast cancer.
Features online, events, awards, newsletter, social media